Class/mechanism: Selective non-steroidal aromatase inhibitor. The aromatase enzyme converts adrenal and ovarian androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in peripheral tissues.
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Patient drug information
- Anastrozole (Arimidex) package insert
- Anastrozole (Arimidex) patient drug information (Chemocare)
- Anastrozole (Arimidex) patient drug information (UpToDate)
History of changes in FDA indication
- 12/27/1995: Initial approval for treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
- 9/5/2002: Accelerated approval for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
- 9/16/2005: Converted to regular approval.
- As of 12/2018, approved for:
- Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
- First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.
- Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Also known as
- Brand names: Altraz, Anabrez, Anastraze, Anastrazol Rontag, Anastrol, Arimidex, Asiolex, Karomex, Leprofen, RUI SI YI, RUI Ting, Trozolet, Trozolite.